text:
Apricus Biosciences (NASDAQ:APRI)
2012 Earnings Call
March 18, 2013 1:00 pm ET
Edward M. Cox - Vice President of Corporate Development & Investor Relations
Steve Martin - Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Treasurer
Richard W. Pascoe - Chief Executive Officer and Director
Jason N. Butler - JMP Securities LLC, Research Division
Robert M. Wasserman - Dawson James Securities, Inc., Research Division
George Santana - Ascendiant Capital Markets LLC, Research Division
Greetings, and welcome to the Apricus Biosciences 2012 Financial Results and Highlights Teleconference and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Edward Cox, VP of Corporate Development and IR for Apricus. Please begin, sir.
Edward M. Cox
Good morning, and thank you for joining us today. I'm Ed Cox, Vice President of Corporate Development and Investor Relations here at Apricus Bio. With me from Apricus is our newly appointed Chief Executive Officer, Rich Pascoe; along with Steve Martin, our Chief Financial Officer and recently interim Chief Executive Officer; as well as Randy Berholtz, our Executive Vice President and General Counsel.
During the call today, we will review the recent corporate events, discuss 2012 financial results and recap the company's upcoming milestones. After which, we will open the call up for questions. Let me remind everyone that during today's conference call, the management team will make forward-looking statements regarding future events or future financial performance of the company. Please keep in mind that such statements are predictions based on current expectations, and actual results could differ materially. You should refer to our most recent filings with the Securities and Exchange Commission for additional discussions on factors affecting our business.
With that, I will turn the call over to Steve Martin. Steve?
Steve Martin
Thank you, Ed. Good morning, and thank you, all, for joining us today. Before we begin, I'd like to take a moment to welcome Rich Pascoe, our newly appointed Chief Executive Officer, and give him the opportunity to introduce himself. Rich brings over 20 years of experience in the life sciences. This includes roles in corporate strategy, global strategic partnerships, product developments, regulatory approvals and marketing and sales. Rich's expertise will be invaluable to Apricus Bio during this pivotal time in our development as a company, particularly as we look to commercialize our lead assets, Vitaros and Femprox, in markets around the world. We welcome Rich to the company and look forward to his leadership and contributions as we continue to execute on our corporate strategy. Rich has also joined Apricus' Board of Directors.
With that, I'll turn the call over to Rich.
Richard W. Pascoe
Thank you, Steve. I'd like to quickly thank the Board of Directors and management at Apricus Bio for both a warm welcome and for the opportunity to help shape the direction of what, to me, is a very exciting story. I look forward to working closely with the team to execute on the company's near-term corporate goals, focusing on creating value through the development and commercialization of these 2 novel and very timely products, which Steve just mentioned, Vitaros and Femprox. I also look forward to updating shareholders on our progress in the coming months as I get more involved in these programs and with the teams here at Apricus.
I'd like to now spend a few moments reaffirming our corporate strategy here at Apricus and then turn it back over to Steve to describe some of the more recent activities. I believe that the core tenet of our streamlined corporate strategy is the company announced at the beginning of this year, will allow Apricus to generate the greatest potential for shareholder value creation. Our focus will be on the further development and commercialization through strategic partnerships of the company's primary commercial and pipeline assets in male and female sexual health. Both Vitaros and Femprox utilize Apricus Bio's proprietary NexACT transdermal delivery platform, a technology with extensive clinical validation and in Canada, regulatory validation. The company's resources therefore will be directed towards these key assets as we concentrate our strategic focus that will better allow us to deliver value through 2013 and beyond.
A key component in executing on this strategy is the divestiture of noncore assets. The company announced in January of this year its intention to seek strategic alternatives towards oncology supportive care business and is actively working with potential buyers for certain assets in its Apricus Pharmaceuticals USA subsidiary. In addition, the company announced last week its intention to cease financing of our French subsidiaries. This decision follows an in-depth cost benefit analysis and evaluation of strategic options, both of which point to this action being in the best interest of the company and its shareholders.
Since Apricus Bio's acquisition of these subsidiaries, change in the French drug reimbursement environment, which strongly favored generic pharmaceuticals, has led to an unforeseen loss of contract revenue and a substantial reduction in the unit's value potential. These decisions will allow the company to dedicate resources to our pipeline assets, for which we have secured numerous partnerships for Vitaros, are engaged in discussions with multiple additional license partners for both Vitaros and Femprox in which -- and which offer the greatest near-term potential for value creation.
I'd like to discuss Vitaros first, our lead product candidate for the treatment of erectile dysfunction. The first important milestone ahead of us with this product is its inaugural commercial launch in Canada. Our partners at Abbott remain fully committed to Vitaros and its launch in Canada. We are actively supporting their prelaunch efforts and continue to expect a full launch in the first half of this year. With this, Vitaros will become the first new and novel erectile dysfunction product launched in nearly a decade. And similar to Viagra, Cialis and Levitra, we believe it is well positioned for commercial success.
The next major milestone for Vitaros is the decision on European approval. This decision will come via the European Decentralized Procedure with Netherlands as the Reference Member State and is expected to occur in the first half of 2013. Following a DCP approval, we can then begin securing national approvals in each of the major markets of Europe. As we have guided recently, we also look forward to an approval decision on Vitaros in Switzerland, a separate regulatory system from the European DCP, in the second half of this year. As these approvals come in, marketing will be initiated in each of the respective countries through our various partnerships. Currently, Vitaros partnerships are in place in key European markets, including the United Kingdom, Germany and Italy, with additional partnership discussions ongoing. Overall, Europe is a $1.2 billion market for existing erectile dysfunction products with what we believe is a very significant untreated and undertreated population. Interest in Vitaros remains strong in many of these territories. And we expect to see additional partnering activity as our regulatory milestones unfold. As many of you know, Vitaros is a topically applied formulation of alprostadil, a vasodilator, which directly increases blood flow to the penis, causing an erection. The current leading medications for erectile dysfunction are all orally administered PDE5 inhibitors such as Viagra, Cialis and Levitra, the fact that leaves a large number of patients who cannot or do not respond well to these medications untreated or undertreated, in addition to the population which is intolerant to these systemic effects of PDE5 inhibitors. Third-party research has detailed that as many as 18% of patients are contraindicated due to medications or current disease, over 20% of patients are nonresponders to the available PDE5, and more than 31% of patients on those drugs drop out after the initial prescription and nearly 50% drop out within 3 years of starting on the medication. These figures give us and our major pharmaceutical partners confidence that there is a substantial market for a product like Vitaros once approved and launched in those markets.
Vitaros takes effect, on average, in 5 to 15 minutes versus 30 to 90 minutes with the oral medications. And unlike the oral medications, they can be safely used by ED patients with hypertension, diabetes, cardiovascular issues or patients on alpha blockers or beta blockers. Alprostadil, the active ingredient in Vitaros, is a widely accepted alternative to the PDE5 inhibitors for these difficult-to-treat patients where previously marketed products were administered by unacceptable means for most patients. We believe that topically applied Vitaros is safe and effective with significantly more market opportunity because of its patient-friendly formulation. Worldwide, this is a market affecting 140 million men and represented $2.6 billion in revenue. Excluding the U.S., Vitaros has represented tremendous value opportunity for us, particularly as a distinct product addressing underserved populations. Our near-term focus for Vitaros is to ensure a successful commercial launch in Canada, to secure additional partnerships with quality development and marketing partners, to continue to pursue regulatory filings in key global territories and to prepare for commercial launches as these opportunities present themselves.
Now I'd like to turn our attention to Femprox, our topical alprostadil cream for the treatment of female sexual arousal disorder, or FSAD. We believe that Femprox has the potential to be the first on-demand treatment for FSAD. The product is currently approved to treat FSAD, and estimates of its market size are on par with erectile dysfunction in males, and perhaps possibly larger. We believe that Femprox is further along in development than any other compound in the space. It's unique among its competitors in that it has a direct and localized mechanism of action. And it's the only product to have successfully completed a nearly 400-patient Phase III clinical trial in China in this indication, one which achieved statistical significance in both its primary and secondary influence.
We have been working closely with Health Canada and the U.S. Food and Drug Administration on determining our next step in the clinic with Femprox and expect to provide an update regarding this development program in the near term. For indications for which endpoints are primarily based on patient reported outcomes measures, such as FSAD, it is essential that methodologies used to measure the endpoints are developed and validated and, of course, agreed to by the regulatory authorities. Setbacks for other companies' products in the overall FSAD state has been largely due to concerns tied to the active products in these drugs almost always either hormone-based or SSRI inhibitors or to very high placebo rates. We believe that Femprox has distinct characteristics, including topical delivery and mechanism of action, separated from other development candidates on several levels. Key elements of our discussions with regulators include trial design. It remains our goal to work with the FDA and other regulatory bodies to build the best methodologies for measuring these desired outcomes.
I would now like to turn the call over to Steve to review the year-end financials and our expected 2013 milestones. Steve?
Steve Martin
Thank you, Rich. I'd like to first turn to the financials. In 2012, we have total revenues of $8.4 million, an increase of $4.3 million over 2011. The increase is primarily due to higher license fee revenue for Abbott and Takeda, as well as second half 2012 revenue from contract sales services related to the French subsidiaries.
Research and development costs increased by $0.4 million to $5.4 million for 2012. This decrease reflects the decrease in contract services related to manufacturing commercial validation batches of Vitaros, which was related to transition of moving Vitaros manufacturing from development to commercial stages.
Selling, general and administrative expenses increased by $3.9 million to $15.4 million during 2012 compared to $11.5 million during 2011. The increases were primarily associated with expenses related to the acquisition and operation of our French subsidiaries. As previously mentioned, we recently ceased funding our French subsidiaries and we anticipate that general and administrative expenses will further decrease as a result of eliminating costs associated with these. The company expects that the most significant expenditures in 2013 will be related to the execution of market approval and commercialization plans for Vitaros, the development and implementation of a regulatory and clinical trial program for Femprox and further development of our pipeline products.
We continued to reduce and closely monitor our operating costs as we move towards commercialization of Vitaros in Canada and Europe. Our net cash used in operating activities was $12.3 million in 2012, and that included approximately $3.1 million related to the French operations.
As of December 31, 2012, we had cash and cash equivalents totaling $15.1 million compared to $7.4 million at December 31, 2011.
In March of 2013, we completed the sale of our New Jersey real estate facility, which provided net cash proceeds of $3.6 million to us. We believe we have sufficient capital and access to capital to achieve our current initiatives and growth plans. We've made tremendous efforts in 2012 towards achieving our goals, which we hope to accelerate dramatically in 2013 and beyond.
To recap, our upcoming milestones include: first, the Canadian launch of Vitaros in the first half of 2013 by our partner, Abbott Laboratories, as a first-line treatment for erectile dysfunction, one of the first ED products to be launched in nearly a decade and a unique product addressing a large underserved population; second, an approval decision for Vitaros in Europe, a $1.2 billion market phase in the first half of 2013; third, feedback from the regulatory agencies, including the FDA, on the next step for Femprox and its clinical development; and then finally, continued partnership discussions for Vitaros, as well as our other pipeline products in major global markets with the goal of signing and announcing additional partnerships.
I'd like to thank the entire team for their ongoing efforts in streamlining our strategic focus. The team is excited and highly committed to seeing Apricus become a market leader. I'd also like to thank our shareholders for their support during my time as interim CEO. We're very excited that Rich has joined us at Apricus. And again, I'd like to welcome him to the team, and I look forward to supporting him in my role as CFO.
Richard W. Pascoe
Thank you, Steve, for that summary. In closing, I want to recognize Steve and the entire team here in Apricus for their outstanding leadership throughout this transition period. And I look forward to working with him and the senior team as we move Apricus Bio forward. With that, we will now open the call up to questions. Operator?
Question-and-Answer Session
[Operator Instructions] Our first question comes from Jason Butler of JMP Securities.
Jason N. Butler - JMP Securities LLC, Research Division
First of all, let me say congratulations to everybody involved for the new appointment of the CEO. Great to see some clarity here. So first question, in Canada, I think it's fair to say that people have been waiting for some time now to see the launch. Can you just give us an idea of what's the -- what has been occurring and what the steps are to Abbott launching the product?
Richard W. Pascoe
Jason, this is Rich. I'm excited to be onboard. What I'd like to say, and I'm going to hand it over to Steve to provide a little more color here, is that we are working very closely with Abbott to support their launch. I applaud Abbott's approach here in terms of being well prepared to launch this product in Canada. We clearly are looking forward to that launch. It's important, given that this is not only our first launch of the product in terms of post-approval perspective, but also we want to make sure that we are being good partners to Abbott, and I think we will continue to do so. As we've said here in our prepared remarks, consistent with past remarks, we anticipate a launch to occur in the first half of this year. And with that, I'll turn it over to Steve to provide a little more color on some of the more recent activities.
Steve Martin
Yes, Jason, it's a good question. We've continued to indicate we have a lot of confidence in the product. We feel good about the opportunity. We are very close with Abbott. As you know, September of last year was when we announced that we achieved the sign off in the commercial batches, and we received $2.5 million. Since then, we worked through the process steps that are typical with any launch, there are stability batches that we've put out for test. We also have marketing steps. We also have sales planning and training. So all those are foreseen, but again, our process has been not to give too much of the detail of a launch led by our partners. So it really is a partner-led product -- project. And we continue to be feel good about the situation. But again, we won't be able to give specific dates or actions that are being planned and incurring by Abbott, other than we will continue to progress and support them all the way to the launch date.
Jason N. Butler - JMP Securities LLC, Research Division
That's great. And could just remind us what the patent protection is in Canada and how long do you anticipate marketing exclusivity or Abbott to have marketing exclusivity?
Steve Martin
Ed, do you want to cover that?
Edward M. Cox
Sure. So it's over 3 different generations. The first co-chain product with patent protection is out 2021, the room temperature formulation is 2026 and the room temperature device and mixing patents, which are pending, is 2031.
Jason N. Butler - JMP Securities LLC, Research Division
Okay, great. And then just in terms of the European approval decision, can you give us an idea of what the recent dialogue with the regulatory authorities has been and what the key points of discussion right now relate to?
Edward M. Cox
Sure. The background is we first filed in 2011. And we indicated recently, we went back on the clock, it's roughly a 210-day process. And we've indicated we'll have our final decision within this first half of the year, considering that there is no other administrative delays. But we have passed the 120-day mark, which means there has been continual questions back and forth. We've continued to be positive about the opportunity to respond successfully because we've been through this cycle in Canada and we were successful there as well. So again, we work closely with our partners. We work closely internally with our regulatory team. But we feel good about the next steps, which include responses due in the near term and then a couple more steps and a decision within this first half of the year.
Jason N. Butler - JMP Securities LLC, Research Division
Okay, great. And then just last question on Femprox. Understand you're still in a dialogue with regulatory authority there, but can you give us any visibility into what you are focused on right now in terms of the trial design, what endpoints you're looking to assess and what the value of the Phase III data in China still represents to you?
Richard W. Pascoe
Jason, this is Rich. I think the focus right now on Femprox is preparing the product for what we hope to be a successful clinical development program. That includes quite a bit of work that's been accomplished internally and in consultation with the regulatory authorities. I don't think we're prepared to go into a great deal of detail right now about that plan. Suffice it to say that it's our intention to provide more clarity on the Femprox development plan. And moreover, the more comprehensive approach that I'd like to take with a product like this at this stage of development is to really look at all the different facets to include market elements, payor elements and the like. And so I'm very confident that the team has been doing the work that needs to be done to prepare that plan. And as we've stated here today, we anticipate providing more clarity as we move forward here in the first half of this year.
Our next question is from Bob Wasserman of Dawson James Securities.
Robert M. Wasserman - Dawson James Securities, Inc., Research Division
Just a question on trends. I know at one time you were going to market that with your subsidiary, Vitaros, I mean, was just approved. Did that change any? Are you going to look for partners now that you're kind of winding that group down?
Steve Martin
As you understand, Bob, it's a step process. So Apricus has made a decision to cease funding. The next steps are really more legal and in France, and so there is a number of decisions that have to be made about the employee base there and the next steps with opportunities for the business. So we haven't probably decided how we'll next move to the French market for the Vitaros product. But it's expected that we probably would not be able to continue with the sales force that's in place. So we'll have to come back to you on how soon we're going to have decision on our plan for Vitaros in the EU. The first objective, of course, to get the products approved through the DCP. And we see that coming well and then we move on to the partner launches throughout Europe.
Robert M. Wasserman - Dawson James Securities, Inc., Research Division
Okay. And one more question, what's your R&D budget for 2013? Is that somewhat flexible depending on some of your other pipeline products or are you pretty much fixed in stone?
Steve Martin
Good question. We've been about mid $5-million-ish number the last couple of years. And there's been a couple different derivations to that. We've spent some time on commercial lots and validation lots for Vitaros with that increase and things slowed down as we move towards commercialization in Canada. What we'll see is that the latter part of 2013 and into '14, we'll start to see clinical trial activity for Femprox, and that will raise the R&D. So I think you would see that the normal run rate is a little bit below $5 million. And then it will certainly ramp up as we decide on the size of the trial, the number of the patients and the speed at which we start to recruit those patients.
Our next question comes from George Santana of Ascendiant.
George Santana - Ascendiant Capital Markets LLC, Research Division
There's been some question, perhaps some buzz, on manufacturing and any issues there. Can you maybe address that for a minute?
Steve Martin
Again, George, that's still part of manufacturing Vitaros. And so we make our products at a facility called Therapex, which is our captive contract manufacturer in Canada. They shipped the product from the former NexMed facility in New Jersey a number of years ago. So they have done all of our engineering batches, our validation batches and our stability batches. So we achieved, in effect, materials December last year. That was a key landmark for the company that triggered our payment with Abbott. And now, of course, we continue to make the batches towards sampling for Abbott and other companies and then ultimately, the commercial launch. So what I would say is I think we are working through the normal processes of evaluation and analysis of any manufacturing process to make sure you have the batch just right. But I wouldn't say there's any unusual manufacturing concerns that we have at this point in time, other than these are what we think our normal processes to make sure you have a commercial batch that's repeatable and accretable over time and in higher volumes, because certainly this is going to be a high-volume product. So we continue to work through that as well.
George Santana - Ascendiant Capital Markets LLC, Research Division
Great. And also just to rationally -- very generally, you've addressed a part of this. But what can we expect for OpEx for the year, because you've got so many moving pieces, of things being deconsolidated and sold off? Just directionally perhaps you can give us some guidance there?
Steve Martin
Yes, I'll cover that. So we had cash use from operations in 2012 of roughly $12.3 million, and that included a little bit of money we used for the French business, which we ceased funding. So we started the year with cash of about $15 million. We added $3.6 million in connection with the sale of our New Jersey building. So that gives us available a little bit more than $18 million. We indicated publicly we have sufficient cash to continue more than 12 months. And so if you look at our $12 million run rate in 2012, I would think before we get to the Femprox trial, we're going to be in that neighborhood. And then it will start to increase in late 2013 and '14 for Femprox.
[Operator Instructions] It appears we have no further questions at this time. I would now like to pass the floor back to management for closing comments.
Steve Martin
Thank you for joining us on the call today. And as always, if you have any questions, please do not hesitate to contact the company directly. Again, thanks everyone, for your time.
This concludes today's teleconference. You may now disconnect your lines at this time. And thank you for your participation.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: email@example.com. Thank you!


text:
If you can't explain your decision in terms a reasonably intelligent 10th grader would understand, you probably need to rethink your decision. - Anonymous
The above saying seems to get lost in the investing community. We investors often tend to think we're a little more sophisticated or well-informed than the general populace, and perhaps we are. Yet in throwing around PEG ratios and operating margins and technical chart patterns, we sometimes forget that there are other equally valid ways of analyzing a potential investment. I am going to use an alternative valuation metric to examine just how overpriced Facebook (NASDAQ:FB) (and Zynga (NASDAQ:ZNGA)) stock is, using an argument a 15-year-old could understand.
What Can I Get With My Money? Devising An Alternate Valuation Metric
One of the first lessons kids learn when they have a little money to spend is that buying one thing often means you can't buy another. If a little boy wants the newest video game console, he may not be have enough cash to buy that BB gun he's been dreaming about. We learn (or rather, should learn) pretty early on that we only have a finite amount of resources, and we should utilize them in a way that maximizes utility/return. (If I opt for the less expensive car, I can take my family on a vacation AND put away some money for my daughter's college, so on and so forth.)
Warren Buffett used this sort of "finite capital" analysis to explain why he didn't like gold as an investment. According to Buffett's reasoning, with a certain sum of money, he could either buy all the gold in the world—and it would just sit there—or he could buy Exxon-Mobil a bunch of times over, buy up all the arable land in America, and still have a trillions of "walking around" money. Buffett's argument is that maximum utility is achieved by buying things that aren't gold.
Gold's potential merit as an investment aside, this seems to be a valid valuation metric to me—after all, it fits in quite nicely with our real-world experience of choosing what to spend our money on. It's a great tool to explain to the layman why Facebook and friends are overvalued. (And you have no idea how many of my non-investor friends wanted to buy Facebook right after the IPO. So they're the ones who I had to explain this to in lay terms.)
As of the time of this writing, Facebook's market cap is $68.82B. In "common man" terms, this means that if you wanted to buy all of Facebook, you'd have to spend $68.82 billion. (Please note that as Facebook's stock price is jumpier than my neighbor's terrier, the market cap may have changed by the time you read this. However, the general point/conclusions should still hold.)
We'll throw in Zynga's $3.82B market cap as well, since Zynga is inextricably linked to Facebook.
Let's now examine what ELSE you could buy for $72.64 billion, then see if Facebook (+ Zynga) is really worth buying. It's especially important to keep in mind that Facebook's future is unknown—it could grow and grow and grow, or it could be replaced by another social network. (Interesting note: Facebook's users are declining.)
What Else You Could Buy
1: J.M. Smucker Company (SJM)
Market Cap: $8.29B
This is the company behind Smucker's Jam, JIF Peanut Butter, Crisco, Folgers, and a bunch of other consumer brands.
2: Hanesbrands Inc. (HBI)
Market Cap: $2.85B
Unless the world is overtaken by nudists, I feel it's a pretty safe bet that we will continue using socks and underwear.
3: The Hershey Company (HSY)
Market Cap: $16.24B
Chocolate and candy. Does anything more need to be said?
4: Clorox Corporation (CLX)
Market Cap: $9.41B
Bleach and stuff.
5: Kellogg Company (K)
Market Cap: $17.4B
Cornflakes and stuff.
6: H. J. Heinz Company (HNZ)
Market Cap: $17.58B
Ketchup and stuff.
Net Income Analysis
Facebook's Q1 net income was $205M, down from $233M a year ago. Let's be generous and give Facebook a yearly income of $1B. So if we spent $72.64 billion on Facebook, we'd be entitled to a yearly income of $1B now, and theoretically more as Facebook grows. Zynga's net income is $182M/yr, excluding stock compensation costs. Again, we'll be generous and call it $250M/yr, for a total income of $1.25B plus growth in the future.
Now let's look at the net income of the other six companies we could have bought.
Click to enlarge
SJM Net Income TTM data by YCharts
Buying these six companies would entitle us to immediate net income of 1.223B + 923M + 668M + 536M + 455M + 191M for a total of $3.996 B, or roughly $4B of immediate income.
Let's say that over time, these six companies grow income at a very conservative 2%. Let's also say Facebook/Zynga grow earnings at a very rapid 25% annual clip. How long does it take Facebook to catch up to these six companies' earnings?
numbers in billions
While Facebook and Zynga start to earn more after Year 7, they don't give us more total return until Year 11. Of course, this is assuming that Facebook and Zynga are able to maintain 25% income growth—as I previously noted, Facebook's income dropped in Q1.
Further Considerations
Another factor the "retail investor" should consider is concentration risk. If you choose to invest a certain amount of capital in Facebook, what happens if Facebook users start leaving? (The all-important teen demographic is already starting to.) Obviously, it will be difficult for Facebook to maintain income in such a scenario. On the other hand, it's fairly easy to predict that over the next 10 years, people will still be eating PB&Js and buying bleach to get stains out of their socks.
Further Analysis and Conclusions
The argument scales down - buying all of Facebook + Zynga is equal to buying all of the companies mentioned, so buying 1/10th of Facebook is equal to buying 1/10th of all the companies mentioned, and so on. So whatever "stake" you have in Facebook could be used to buy an equivalent "stake" in each company mentioned.
I believe this argument I've constructed is fairly easy for the average layman to understand: you can either buy X, or you can buy A, B, and C. Taking it one step further, buying A, B, and C enables you to collect more income than buying X. Also, you know that A, B, and C will have a fairly stable customer base, while you can't predict what will happen to X's customer base.
Presented with the data above and a $72 billion bank account, I think a reasonably intelligent 15-year-old would choose to buy A, B, and C rather than X.
In conclusion, Facebook might make a good "speculative" play for investors with cash to burn, but it should not be a core portfolio holding for retail investors with smaller bank balances. Why? Simply put, you have to take on a lot more risk (sacrificing immediate income) for the possibility of future returns that may never materialize.
So if you really want to buy Facebook, sure, buy a dozen or so shares. But don't invest more than you feel comfortable losing.
For more analysis on Facebook, see Facebook and the Email Snafu: A Troubling Trend?
Disclaimer: I am an individual investor, not a licensed investment advisor or broker dealer. Investors are cautioned to perform their own due diligence. All information contained within this report is presented as-is and has been derived from public sources and management. Always contact a financial professional before making any major financial decisions. All investments have an inherent degree of risk. The future is uncertain, and actual results may be materially different from those expected. Past performance is no guarantee of future results. All views expressed herein are my own, and cannot be interpreted as the views of my employer(s) or any organizations I am affiliated with. Presentation of information does not necessarily constitute a recommendation to buy or sell. Never make any investment without conducting your own research and reading multiple points of view.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

subset: commoncrawl


text:
The films of the great Japanese directors
Three names synonymous with classic Japanese cinema, all very different from each other with their own style yet each in their own way masters of cinema and highly influential.
Mizoguchi, an extremely humanist director especially where the suffering of women was concerned. He created films of subtlety, simplicity but with so much depth, a large number of his films are set during Japans feudal period and deal with peasants, geishas and prostitutes rather than the grand scale epics that Kurosawa is renowned for. Seen by some as the greatest Japanese director of all time.
Ozu, famous for his static camera work, minimalist approach to plot and films about life and the family, also showing the changing face of post-war Japan, its only in recent years that his name and films have become better known in the West as the films were seen as being too Japanese for a Western audience. Thankfully more of his films are at last seeing the light of day.
Kurosawa, probably the most well known Japanese director in the world, from the Samurai epics like Seven Samurai through to Ran to the smaller scale of Ikiru and Dersu Uzula, Akira Kurosawa was lauded on the world stage far more than he was in Japan where he often had great difficulty raising the money for his next project.
Please feel free to add your own comments, reviews and criticisms to this thread.
Insight to Mizoguchi by Johndav
Sansho the Bailiff (1954) - Review by wpqx
Sansho the Bailiff (1954) - further notes by Johndav
Late Spring (1949)
Early Summer (1951)
Tokyo Story (1953)
The Only Son (1936) - Review by johndav.
Good Morning (1959) - Review by wpqx
End of Summer/Early Autumn (1961) - Review by wpqx
The Seven Samurai (1954) - Review by wpqx
Throne of Blood (1957) - Review by wpqx
Ikiru (1952) - Review by wpqx
Rashomon (1950) - Review by wpqx
Rhapsody in August (1991) - Review by wpqx
Rhapsody in August (1991) - Review by Howard Schumann
Still to come.
For other sections of Japanese Journals, please use the links
2. Kurosawa, Ozu & Mizoguchi - The Classics
3. Kitano, Tsukamoto & Miike - The Modern Cult Directors
4. Anime
5. Horror & Ghost Stories
6. Jidaigeki (Chambara)
Cheers Trev


text:
RUSH: I'm sitting here thinking more about the ideology of intolerance, the classic liberal. That intolerant teacher in North Carolina was a bully, telling her students that it was criminal to criticize Obama. You know, when you get right down to it, maybe one of the best ways to explain liberalism to the uninitiated is to simply say that it is intolerant. It's a philosophy of "no." It's a philosophy of domination and "no," and it's not at all what people think it is.
It's not open-mindedness. It's not tolerance. It's not good intentions. It's not sweetness and light and love and all that. It's a philosophy of "no." It is intolerant. Socialism, fascism, communism, all forms of liberalism dictate behavior. You must conform. Individuals? Private businesses? You must conform to what they say. And if you don't they'll pass laws and regulations that force you to. And in order to have uniformity, there must be an enforcement mechanism, because people are not the same.
People don't want the same things. They don't believe the same things. But if you are going to have uniformity -- which is what liberalism wants, 'cause that's equality to them: everybody being the same. Outcomes especially. Being the same. Nobody richer than anybody else. If you are to have that, you must have an enforcement mechanism that shuts down what? Creativity, choice, and innovation. You have to shut down all the things that differentiate people.
And in a free society, the things that differentiate people are creativity, choice, and innovation. And that has to be shut down. That is why, folks, an ever-expanding government is job one for liberals. Whatever expands government, whatever makes it bigger: Global warming, feminism, amnesty for illegals, whatever. Whatever needs more regulation, whatever needs more control, is sought "for the common good" and uniformity.
"It's all for the common good," they say. But anything that grows the government, that's job number one for liberals.
Government is the enforcement mechanism.
Government is the practical manifestation of the ideology of "no."
Government is where the intolerance is.
Government is the all-powerful engine that prevents innovation and choice and creativity.
Look at that slideshow that Obama did: "Julia." That's how you remake millions of individuals in 50 states into a faceless cartoon. You have a cartoon for your own reelection and you come up with a fictional character: Julia, the average American woman who turns to government at every stage of her life when she needs or wants something. Not a husband, not a family, not a church, but to the government.
The government makes her birth possible.
The government makes her prenatal care possible.
The government makes her garden possible.
Except it's not hers. It's a "community garden."
So now you have Obama dictating a uniform health insurance policy that has to be purchased by all Americans. HAS TO BE! It's enforced by a fine. It says "no" to individual needs and wants. If you don't want health insurance, that doesn't matter. You have to buy it. If you don't buy it, there is a fine. A moratorium on drilling for oil in the Gulf of Mexico. That is the government saying "no." And the enforcement mechanism is the government.
"No" to jobs.
"No" to cheap energy.
Regulations are variations of the "Just say 'no'" theme. Regulations are how liberals "just say 'no.'" Regulations are how they enforce their own intolerance. Regulations and laws are how they enforce their mandated behavioral codes. Obama has said "no" to any budgets. The Democrat Party has said "no" to budgets. Obama has said "no" to the Keystone pipeline. Obama has said "no" to reforming entitlements! He has said "no" to doing anything about runaway debt.
It's all "Shut up and sit down, America! Do as I say and there won't be any trouble."
And that's what liberalism is.
It all stems from a mind-set of intolerance.
"Don't you criticize Obama! That's criminal! You can't criticize a sitting president! That's sedition; you can't do it."
And the student says, "It's free speech, my First Amendment right."
"There isn't one here!"
So liberalism is a mind-set of total control. It's why our schools now favor indoctrination over education. See, freedom of thought is bad to them. We see example after example, be it what you bring from home for lunch or what you say. Lunch from home is not even tolerable! What you bring from home for lunch, a federal agent can regulate! Uniformity is the goal. That's liberalism, where the people reflect and represent the views of the state, not their own.


text:
The Meaning of RR
You have found the definitive source for the meaning of RR. This page contains all the definitions of RR, crowd sourced, moderated and curated by real people who care about the true definitions of RR.
The Top Definition of RR
The most popular meaning of RR is: Reply Required
What Other Meanings of RR Are There?
- rest room
- Restroom
- Add your own definition of RR.
What is RR?
RR is Reply Required
RR Means
The definition of RR is "Reply Required".
RR Definition
The meaning of RR
RR means Reply Required.
Now you understand the definition of RR - RR means "Reply Required".
We're glad to be of assistance. Click here to thank us:
What does RR mean? RR is an acronym, abbreviation or slang word that is explained above. If you ever forget what RR means, just come back to Slang.org and we'll define any acronym you need help with.


text:
Set in picturesque countryside along the banks of the river Cree, the small town of Newton Stewart is a haven for anglers and walkers on a cottage holiday. Nature is at its most abundant in this region, where the Galloway Forest Park provides a good starting point for ramblers and nature lovers, and is home to southern Scotland's highest peak, Merrick, which is set within more than three hundred square miles of spectacular forest park, woodlands, mountains and lochs. Birds of prey are common here, and birdwatchers can hope to find red kites, buzzards and maybe even a glimpse of a golden eagle.
Archive for December, 2011
The Sykes Cottages Guide To Newton StewartThursday, December 29th, 2011
The Sykes Cottages Guide To ReethFriday, December 23rd, 2011
Reeth is a lovely place to visit and explore on a cottage holiday. Just a few miles from Richmond, Reeth lies at the junction of two of Yorkshire's most northerly dales, the beautiful and tranquil dales of Swaledale and Arkengarthdale. A tiny, traditional Dales village, built around the village green, life continues here today seemingly little removed from the way in which it has over centuries. It is precisely this quintessential village character which makes Reeth a popular place to visit today.
The Sykes Cottages Guide To Combe Martin and ExmoorThursday, December 22nd, 2011
Combe Martin
Explore Combe Martin and Exmoor on a cottage holiday. The village of Combe Martin is located where Exmoor National Park and the North Devon Area of Outstanding Natural Beauty meet, it really is worthy of a mention simply for the pure picturesque nature of its setting. Whitewashed houses, pleasant pubs and beautiful coves off the main beach nestle between the two main headlands protecting the village. A walker's paradise, sections of the South West Coastal path pass through Combe Martin, whilst visitors must see also the neighbouring delightful ancient village of Berrynarbor. (more…)
The Sykes Cottages Guide To Wymondham, Diss, Harleston & HinghamFriday, December 16th, 2011
The many historic towns and villages found to the south of Norwich, between the city and the county's border with neighbouring Suffolk, are well worth visiting on a cottage holiday. Visit the Roman settlement at Caistor St. Edmund just south of Norwich, or discover beautiful Diss, a delightful market town offering sixteenth century timber-framed houses built around the six acres of Diss Mere Lake. The walking route of Boudica's Way starts here, and ramblers can make the journey back to Norwich along this famous trail. Harleston holds a market every Wednesday, whilst the village of Hingham boasts a plethora of period buildings. (more…)
The Sykes Cottages Guide To EllesmereTuesday, December 13th, 2011
Make sure to spend some time in Ellesmere on your Shropshire holiday cottage break. A delightful town on the site of an ancient Roman settlement, Ellesmere centres on a beautiful glacial lake. There are many different ways to enjoy it; take a boat out on the water and indulge in a spot of fishing or bird watching, board a steamboat or watch for herons and other wildlife from the warmth of the Visitor Centre. Take a ramble along the lakeshore before following the Llangollen canal towpath into town, passing the home of the legendary engineer, Thomas Telford, en route.


text:
SYNOPSIS: An Horror Movie directed by Masafumi Yamada starring Hirofumi Araki, Mayumi Asaka and Aika Ohta.Read More »
Home | Tag Archives: Masafumi Yamada
Tag Archives: Masafumi Yamada
Film Review: Hide and Go Kill 2 (2009)
SYNOPSIS: When her classmate Ritsuko disappears, her friend Ryoko is desperate to find her. When she discovers that Ritsuko was playing a strange game online of hide and seek, she begins to wonder if it could be related to her disappearance somehow. Ryoko then discovers that the game is more sinister than it appeared at first. It is linked to …Read More »


text:
This procedure provides guidance on the formal coordination of the Department of Energy (DOE) Technical Standards in the DOE Technical Standards Program (TSP). The purpose of coordination of draft DOE Technical Standards is to solicit and receive comments from interested persons and organizations in order to improve and correct DOE Technical Standards. DOE Technical Standards are coordinated through the electronic TSP RevCom process.
This procedure applies to all DOE Headquarters and field organizations, management and operating contractors, integrating contractors, and laboratories (hereafter referred to collectively as TSP participants) working to the latest revision of DOE Order (O) 252.1A,Technical Standards Program.


text:
Home List of Titles Investigation of cell shape effect on the mechanical behaviour of open-cell metal foams
Please use this identifier to cite or link to this item: http://hdl.handle.net/1959.3/215480
- Title
- Investigation of cell shape effect on the mechanical behaviour of open-cell metal foams
- Author(s)
- An, Yang; Wen, Cui'e; Hodgson, Peter D.; Yang, Chunhui
- Abstract
- The mechanical behaviours of metal foams greatly depend on their cell topology, including cell shape, cell size etc. as well as relative density and material properties of the cell wall. However, the cell shape effect on the mechanical behaviours of such materials appears to be ignored in previous research. In this paper, both analytic and finite element models are developed and employed to investigate the effect of cell shape on the mechanical behaviour of open-cell magnesium alloy (AZ91) foams under compression, including deformation modes and failure modes. For numerical modelling, both two-dimensional (2-D) and three-dimensional (3-D) finite element models are developed to predict the compressive behaviours of typical open-cell metal foams and capture the deformation modes and failure mechanisms. Two typical cell shapes i.e. cubic and diamond are taken into consideration. To validate these models, the analytic and numerical results are compared to the experimental data. Both the numerical and experimental data indicate that the cell shape significantly affects the compression behaviour of open-cell metal foams. In general, numerical results from the three-dimensional solid-element model show better agreement with the experimental results than those from other finite element models.
- Publication type
- Journal article
- Research centre
- Swinburne University of Technology. Faculty of Engineering and Industrial Sciences
- Source
- Computational Materials Science, Vol. 55 (Apr 2012), pp. 1-9
- Publication year
- 2012
- FOR Code(s)
- 0204 Condensed Matter Physics; 0912 Materials Engineering
- Keyword(s)
- Cell shape effect; Deformation mode; Effective Young's modulus; Failure mechanism; Finite element modelling; Open-cell metal foams
- Publisher
- Elsevier
- 0927-0256
- Publisher URL
- Copyright
- Copyright © 2011 Elsevier B.V. All rights reserved.
- Peer reviewed


text:
I am not sure what I am supposed to comment! This is a topic with room for debate. I will therefore look at it from a tourist perspective. Generally as a tourist, we look for something different to where we live. For that reason, walking through this district was rather interesting. I also learnt much from the walking tour.
Take a walk to the infamous Red Light District in Amsterdam anytime of the day and you'll be surprised how well their sex industry is thriving there! Watch pretty/unpretty, tall/short, plump/slim and hot/not-so-hot women of all ages (legal that is!) parade their stuffs in windows that flank the Red Light District. See how they flirt with the passer-bys and you'll understand how this sex trade works in Holland!
On our way to the redlight district we pass the old taxcollectors office, a beautifull building, it is built in 1638 by Jacobus van Campen. The merchants who docked their boats here had to pay taxes on beer, tabacco, wine and grain.
On the facade we see two shields. The left one is historical not correct it is a koggeship with a french flags in front. The right shield has the flag with the three crosses of Amsterdam and is topped with an emperorscrown. A city flag may never have an emperorscrown in the heraldry.
But it is nice to look at....
Address: Oude brugsteeg
This is one person wide so one person at a time please.
Sorry, don't remember the name of the straat (if it has one) but I believe it is between Zijds Voorburgwal and Warmoesstraat in the Red Light District.
RED LIGHT DISTRICT: Prostitution is regulated here & licensed brothels surrounding the Oude Kirk with street houses displaying their wares behind plate-glass windows. You can drive past the 17th century homes & observe the storefronts where women half-naked are watching TV, reading books & darning socks while waiting for customers to come along. I was told these ladies even pay taxes & have regular medical check-ups & health coverage provided by the state!
Take a peek at the city's infamous Red Light District. Amsterdam is definitely THE undisputed SEX capital of Europe (like what Bangkok is in Asia). Did you know that the hoertjes (hookers) here are completely LEGAL? You'd find them behind the windows scantily clad.... reading, sewing, staring back at you(!) etc. whilst waiting for customers. And believe me, you'd know when they are bussssy with a customer. :-) The curtains will be shut! I don't mean to sound rude or what, but some of these ladies are really quite unattractive (by human standards) and some are as old as your grandmother.... DON'T even try taking a candid photo of them.... You'd land yourself in HOT soup (read: pimps will go running after you). I have NEVER seen this many MEN looking soooo eager before in my life either (read: eyes twinkling... salivating... the works!).
Ladies, DON'T come here unescorted. Believe me, you wouldn't want to be mistaken as one of these 'ladies of the night'. Ahem! Make sure your boyfriend/ the guy you're with have his arms around your shoulders - ya know... in a protective manner. :-)) If he isn't doing it, TELL HIM SO!
Photo Below: My friend and his brother (those brave guys!) standing right in the middle of the Red Light District here in Amsterdam. Er... what were you guys doing there, pray tell? :-)
The Red Light District. Whatever you do don't take pictures of the "working women" behind the glass. I had read about this before but I sister hadn't so she did! The women in orange grabbed for the door, ran out of her room, yelled "maricon" and a couple other things I couldn't understand then threw a full can of Hienikin at my sister. Luckily it didn't hit anyone (but landed too close to my legs for comfort).
..I searched all around for those red lights everyone was talking about.They are in the upper left corner of the picture..see??...some pretty girl with a cute tatoo sitting in a storefront was more than happy to point them out to me.Thats my story..and Im sticking to it.
Youll notice all the guys in the picture seem to be looking to the right..thats because the girl had a habit of sitting in the windowfront in her underwear.
Hmmm..doesnt she realise if she does that, people will stare????....LOL
The red light district in Amsterdam, is world's famous and it has been around for quite a long time.


text:
Dear members,
Thank you, NarutoBase Staff
Dude. If Naruto rips off another arm, I seriously want to see him slap someone with it just for laughs, even of it does absolutely nothing.
Obito is a Criminal, he lost his way. But there is something some whores should understand here.
1. He turned to a good way (of Course after TnJ-ed by Naruto - "A Hokage is the man who stand the others' pain") and helped The Team 7.
2. I Agree when Naruto Said that Obito is the Coolest Guy. Why?? C'mon Open your Eyes!! he always Sacrifices for his friend. it is twice for Kakashi. (Of course this last one was pretty lame). THERE IS NO GREATER LOVE THAN SACRIFICING.
Originally Posted by Sigma 103
Dude. If Naruto rips off another arm, I seriously want to see him slap someone with it just for laughs, even of it does absolutely nothing.
Okay, that's pretty dang funny! Wish I thought of that sooner
Reminds me of hitting a guy with glasses (LOL).
Nardo > Sauce
Damn..there goes the eyes....crumble to dust. Obito should have given kakashi his eyes before he died.
I think, everyone is forgetting d fact that sakuke is d decoy now, so didn't wanted to distract kaguya for naruto, but dat speed undermine sakuke
"Next chapter: Naruto burns with anger"...
And now that he's ripped off Kaguya's arm, she'll probably get angry, too when she sees how angry he
has become...
and her anger will wipe off Naruto's anger like a wisp of smoke in a storm...
But thankfully, Kishi has it all planned out...with the Kages and all...
Would like to see what those dead guys are up to...
we get to see naruto mad and now we know that sasuke's ps can indeed harm kaguya
rip obito
Originally Posted by riley freeman
we get to see naruto mad and now we know that sasuke's ps can indeed harm kaguya
rip obito
It didn't.
Rest in peace Obito. F+_K that B**** right in the Pu**y
Originally Posted by Man of Sin
It didn't.
pushed her away so it affect her
I'm always happy to see Naruto and Sasuke working together. I'm more worried about BZ than Kaguya now. He was a funny guy. Perhaps he has something else up his sleeve. Lol I hope that Kaguya acts on her own now that BZ was removed. I was expecting this chapter to have a bigger focus on Kakashi's feelings towards the death of Obito. I guess we'll probably see that next chapter.
Last edited by Princess Kaguya; 08-05-2014 at 09:44 PM.
Reason: Spelling error.
Forum Rules


text:
Though fashion, public health, and social activism may seem like entirely separate fields, Kavitha Das, Dental '09, has found a career where they go hand in hand.
Das is the coordinator of the upcoming Diwali Fashion Show and Party, which will be held Oct. 17 at Lair Lounge. The show is being sponsored by Lend-A-Hand India, a New York-based nonprofit that provides vocational training, career development, employment, and entrepreneurial opportunities to young boys and girls in rural and urban Indian communities.
The Diwali Fashion Show will feature unique Indian jewelry by designer Hetal Kothari and the Tijorie Jewelry line, as well as a clothing collection by Vasu Gandhi. The designs are styled around Indian sensibilities for the festive Diwali season. All proceeds from the event will go toward LAHI's projects in India.
Isabel Narea talked to Das about drawing from her Columbia experience in this new endeavor.
Isabel Narea: What was the most memorable aspect of your Columbia experience?
Kavitha Das: Being able to approach my education with a unique angle, as I studied public health and dentistry at the same time. My public health background made me become involved in nonprofits early on. While at Columbia, I worked with many NGOs in different capacities and helped coordinate many different events with different organizations. Becoming involved in Lend-A-Hand India was simply the next step for me.
IN: Why did you become involved with Lend-A-Hand India?
KD: As an Indian interested in working for NGOs, I wanted to get involved with an organization that was authentic and doing something that was needed. The unemployment situation had been going on in India for years. LAHI wanted to make a difference by giving these kids the life skills and training to make a living. I enjoy being involved in LAHI because I know that what we do here is going toward changing the life of a child. If you think about 40 dollars for us, it's really nothing. But that one expenditure can change the entire life of a child in India. To be affiliated with an organization that is helping kids in a way so that they can eventually sustain themselves is a phenomenal thing to do, and the impact it has on the child is enormous. I also knew there was a lot of energy involved in the organization after meeting the officers and staff and knew this would make the experience more fulfilling.
IN: What inspired you to choose fashion as a venue for your activism?
KD: While LAHI often hosts panel discussions, I wanted to approach the project by using something that is unconventional. People come back from a long day of work and want to attend an event where they can relax and enjoy themselves. I also took on the project with my contacts in mind—including clothing designers, jewelry designers, and small-business owners such as caterers who contribute to the event. The show allows fashion designers to make a mark in the fashion world, and the show eventually becomes a publicity event for both the designer and the NGO. It also allows for a little bit of lightheartedness and a good time toward a good cause—and New York is one of the fashion capitals of the world.
Lend-A-Hand India's Diwali Fashion Show and Party is Oct. 17 at 6:30 p.m. at Lair Lounge, 201 Lafayette St. Tickets can be purchased at the door for $40 or online for $30.


text:
I am using squid to accelerate a site I am developing
I have configured a port for squid to listen to port 8080
The site is at the internal address 10.9.8.68:8102
I have configured: httpd_accel_host, httpd_accel_port with their internal
network values
Also added the following lines: acl acceleratedHost dst 10.9.8.68, acl
acceleratedPort port 8102
When the site is visited internally, ( using the internal network address),
everything works fine.
When I visit the site externally, (using the external address), and the
direct port then again everything is fine.
When the squid port is used then it all goes awol the text appears but
images dont appear because the site thinks I am visiting through the
internal network
Any help will be appreciated
Stelios Issaias
Lead Developer
Amaze Ltd
Tel: +44 (0)207 332 5620
Fax: +44 (0)207 248 4082
Email: email@example.com
Web: http://www.amaze.com
Received on Wed Feb 20 2002 - 08:32:57 MST
This archive was generated by hypermail pre-2.1.9 : Tue Dec 09 2003 - 17:06:28 MST


text:
Since its inception, the United Nations Environment Programme (UNEP) had a special relationship with civil society in tackling environmental issues. The Stockholm Conference on Human Environment, which led to the creation of UNEP in 1972, owed much to the enthusiasm, dedication and commitment of civil society. Many multilateral environmental agreements - Basel Convention, Montreal Protocol, Biodiversity and Climate Change Conventions, among others, were developed thanks to the lobbying efforts of civil society.
UNEP recognises the importance of engaging Majors Groups and other Stakeholders as partners and appreciates the perspectives they bring to the table, valuable research and advocacy functions they perform and their role in helping foster long-term, broad-based support for UNEP's mission.
Intergovernmental decisions will have stronger and broader recognition and support by the public if governments take Major Groups and other Stakeholders views into account as early as possible in policy-making and decision-making processes. Major Groups and other Stakeholders also play a direct role in the formation of policy as researchers, think-tanks, and watchdogs, or through advocacy.
After the Earth Summit in 1992, UNEP adopted the Major Groups approach as defined in Agenda 21, the action plan of the United Nations related to sustainable development. In the spirit of Principle 10 of the Rio Declaration from 1992, Rio+20 recognized that sustainable development requires the meaningful involvement and active participation of all nine Major Groups.
The Rio+20 outcomes reaffirm the key role of Major Groups and Stakeholders to achieve sustainable development and underscore in Paragraph 43 of the outcome document that "broad public participation and access to information and judicial and administrative proceedings are essential to the promotion of sustainable development".
Major Groups and Stakeholders Branch
UNEP will continue to encourage their active participation and enhanced ownership in processes that contribute to decision-making, planning and implementation of policies and programmes for sustainable development at regional, sub-regional and national levels.
In 1999, UNEP created a Major Group & NGOs Unit in its Policy Branch to provide Major Groups with a chance of broad participation in environmental decision-making. By creating the Major Groups and Stakeholders Branch in 2004, UNEP continued to enhance participation of Major Groups and other Stakeholders in its work. According to its mandate, the Major Groups and Stakeholders Branch engages with organized constituents such as not-for-profit organizations, networks and associations in contrast to single businesses or individuals.
In order to support strategic partnerships in the most effective way, UNEP distinguishes between three different forms of partnerships:
Participating and engaging in international environmental policy
UNEP commits to facilitate input resulting from Major Groups and other Stakeholders expertise and views, at the intergovernmental level, in line with applicable rules and regulations. Accredited Major Groups and other Stakeholders are invited to participate in all relevant global and regional fora, in particular the United Nations Environment Assembly (UNEA) of UNEP Sessions as well as its Special Sessions including its preceding and associated Global Major Groups and Stakeholders Forum (GMGSF). Major Groups and other Stakeholders are invited to provide their input into the preparatory process, including agenda setting and into the UNEA Sessions can comment and provide expertise also during the preparatory process. Decisions then taken by member states at the UNEA serve as the basis to UNEP's Programme of Work.
Providing scientific and technical expertise
A principle mandate of UNEP is to monitor and assess the global environmental situation to ensure that emerging environmental problems of wide international significance receive appropriate and adequate consideration by governments. UNEP's role in undertaking and organizing assessments consists of catalysing the efforts of the scientific community around environmental topics and collaborate with those networks to undertake the assessment or reporting activities. UNEP undertakes those collaborative global and regional environmental assessments such as the Global Environment Outlook (GEO) report.
When implementing its Programme of Work, UNEP relies on implementing and executing partners from Major Groups and Stakeholders, relying on their expertise, capacity building and outreach abilities and regional, national and local presence.


text:
Music that defined a generation. Watch Ed Sullivan's Rock 'n' Roll Classics.
By Mia Laurenzo • Aug 7, 2014
Ed Sullivan's Rock 'n' Roll Classics: The 60's (9:30 pm)
From the late 1940s until the early 1970s, the greatest music acts in the world were seen by millions of viewers of all ages each Sunday night on "The Ed Sullivan Show." Now, the MY MUSIC series presents a special of classic song performances spanning the years 1963-1968 in ED SULLIVAN'S ROCK AND ROLL CLASSICS: THE 60. From the Beatles' American television debut in 1964 to the Doors' infamous one-time-only appearance, "The Ed Sullivan Show" served up an unparalleled roster of timeless artists.


text:
The HLA alleles and the allele alignments data are obtained from IMGT/HLA database (IMGT/HLA release version 3.10.0, October, 2012). Please refer the following publications for information regarding the IMGT/HLA database and the hla.allele.org database:
A complete list of all of the HLA sequence features and their variant types can be found in the Supplemental Tables to Karp et al (2010) Human Molecular Genetics 19(4):707-719.
For more information on the sources of data for the MHC component in ImmPort, please see below.
Fields marked with an asterisk * are required.
To find allele records for a given MHC locus:
To view alignments for a specific allele or set of alleles:
To view sequence features and sequence feature variant types for a specific allele or set of alleles:
|Allele Search Using Option
|Example Allele Search Text
|Allele Name
|A*02:07 or A*0207, or 02:07 or 0207or any comma-delimited combination
|IMGT Accession Number
|HLA00012 or 00012
|IMGT/HLA G-Code Group Code
|A*01:01:01G or 01:01:01G or A*01:01:01 or 01:01:01
|IMGT/HLA P-Code Group Code
|A*01:01P or 01:01P or A*01:01 or 01:01
|Protein Sequence
|FASTA sequence (no spaces)
|Transcript Sequence
|FASTA sequence (no spaces)
|Common and Well-Documented (CWD) HLA alleles refer to those alleles that have gene frequencies of > 0.001 in any reference population or have been observed in at least three independent, unrelated individuals.
|G-codes describe groups of HLA alleles with identical sequences in the exons encoding the MHC antigen recognition site (exons 2 & 3 in class I MHC genes and exon 2 in class II MHC genes).
|CWD alleles and g-codes are described in the paper, "Common and Well-Documented HLA alleles: Report of the Ad-Hoc Committee of the American Society for Histocompatibility and Immunogenetics" [17462507].
|G-code grouping data was enhanced with ambiguity typing data obtained from Anthony Nolan, [IMGT/HLA Database].
|Population data used for generation of allele frequencies was obtained from dbMHC, [Human Anthropology].
|HLA sequence features and their variant types are described in the paper "Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis" [19933168]. Tables containing detailed descriptions of all HLA SFVTs can be found here.


text:
Thanks to the wild success of the Marvel Cinematic Universe, each and every film studio that owns the rights to a grouping of comic book characters is struggling to match Marvel/ Disney's success by creating their own world of team-up films buttressed with a constellation of interconnected spin-off films. Warner Bros. is using the Man of Steel franchise to introduce/ launch Batman and Wonder Woman, which will in turn lead to an eventual Justice League film, and Sony is using the Spider-Man franchise to launch a series of villain spin-off and team-up films.
And then there's 20th Century Fox, which is having to go the other way around. They've already established their superhero team-up films—X-Men, X2, X-Men: The Last Stand, X-Men: First Class, and the upcoming X-Men: Days of Future Past and X-Men: Apocalypse—and their now working to build an interconnected series of individual hero spin-offs. So far, only Wolverine has received the solo film treatment. But according to a recent interview with producers Lauren Shuler Donner and Simon Kinberg in Entertainment Weekly (via /Film), characters such as Gambit, Deadpool, and Mystique may be getting their own flicks soon.
According to Donner, "there was a regime [at the studio] that didn't see the worth in [spin-offs], and the current people who run Fox understand, embrace it, and we're going to do right by it," Donner said. "I'd like to do Gambit. I'd like to do Deadpool. We'll see. There's a lot of really great characters."
Kinberg added that he loved Jennifer Lawrence's approach to the shapeshifter Mystique, "and I feel like because she is in such a crowded ensemble, there's so much more opportunity if you were to follow her solo."
Now that it's established that audiences will gladly accept an interconnected series of comic book films, don't be surprised if you see a Gambit or Mystique film in your multiplex within the next few years. But between now and then, you can see X-Men: Days of Future Past on May 23.
What do you think of the X-Men news?


text:
Richard Donner's Superman is really two films. Mostly, it's a bouncy comic book adventure, a silly jaunt that paints it's drama and conflict with the same broad strokes and bold colors of the original comic. Unfortunately, it's also a delivery vehicle for joyless sci-fi monologues. Fortunately, the rest of the film **ehem** flies by, carried mostly by Reeve's goofy charisma and dopey do-gooding.
Opening with a 5-minute lazerific credit sequence, director Richard Donner makes clear his intent to A) assault the senses and B) do it very very slowly. The adventure begins on Krypton, a day-glo planet made of plastic and tin foil which is powered by hula-hoops. Donner keeps the audience on the edge of the back of their seats with a riveting look at the inside workings of the Kryptonian legal system, judicial and congressional branches both.
Ah, but these myriad learnings of governmental protocol are all for naught when the planet is blown up by its own inability to contain gooble energy with is yakkity blah blah hoops of power something something. For humanity's benefit, the baby who will become Superman is launched off of Krypton and into a special effects montage where he flies through hundreds of thousands of miles of heavy metal record covers before landing in (the much cheaper to film) Smallville.
It's here that Donner finds his legs, finally injecting the film with humanity and intrigue. His is a Norman Rockwell America, with a teen-filled jalopy in every garage and a microscope on every desk. And, it works in the films favor – it's hard to resist the go-get-'em gumption with which he directs and simply impossible not to get swept away in the scope of the wide open mid-west.
It's all quickly torn away as Clark finds himself short a family member and bound for Metropolis in hopes of finding his fortune. And, find it he does at The Daily Bugle. Sorry, The Gotham Gazette. Sorry. The Daily Planet. From there, it's Super-by-the-numbers. Clark and Louis meet cute, court cute, fly cute, and recite internal poetic monologues in broken meter cute. All the while, Lex Luthor devises a plan to steal California. Because what else would a super villain do?
Having been made before Burton re-wrote what the superhero format could be, this iteration of Superman falls into all the campy trappings laid forth by the source material and decades of low-budget serials. As entertainment, the film mostly plods forward amicably. As an effects extravaganza, Superman is beyond dated. The once epic visual effects would embarrass even the most amateur video enthusiast playing around in his garage these days.
The film's greatest special effect is Christopher Reeve himself – the very definition of a crowd pleaser. He's sweet, silly, humble and handsome as hell. He somehow even manages to laugh off logistic absurdity that is the third act with such jovial confidence that the audience can't help but give in, no matter how mind-bendingly stupid the plot really is.
Worth the pocket-change price of admission? Yes! Absolutely. Just skip forward until Clark gets to Smallville.
What the 13 year-old boy in all of us needs to know about this film: Marlon Brando is in this movie because of course he is.


text:
One Step Ahead makes a great Cozy Cub collection of gear designed to keep your child toasty warm in cold weather from coats to snow pants to mittens and snow boots. They all coordinate for a complete outfitted look.
One Step Ahead Cozy Cub Kids 3-in-1 Snow Jacket
I like the design on this coat because it is a triple value- you get three versatile jackets in one! It's a cozy fleece jacket (great for fall), it's a water-repellent parka (perfect for spring), or zip them together, and it's a great kids' ski jacket (to keep kids warm all winter long!). Hard to outgrow: the sleeves feature no-sew, quick-release seams that add 1½" in length when it's needed. (I have never heard of that feature before- wow!) This kids 3 in 1 snow jacket also features a long, extra-coverage back, fitted, peel-away hood, and gusseted wrists to keep the cold out.
One Step Ahead Cozy Cub Kids Snow Pants
These One Step Ahead Kids Snow Pants are rugged, reinforced, and water-repellent. Your child should get a lot of wear out of these snow pants since you can snip the hem stitch to release an extra TWO inches of length! Converts instantly from snow bibs to snow pants; just zip off the bib. Toasty but not bulky, thanks to their triple-layer warmth technology. Designed for warmth and comfort with stay-put stirrups, silky lined legs, and an elastic-back waist.
One Step Ahead Cozy Cub Snow Jacket and Snow Pants Giveaway:
Two lucky readers will each win one Cozy Cub One Step Ahead 3-in-1 Snow Jacket and Snow Pants. (Winner chooses from available sizes & colors-each set valued at $109.90)
One Step Ahead Kids Giveaway Dates: January 24- February 11 Midnight CST
How to Enter: Enter through Giveaway Tools- just sign into the widget and click the entries you want to complete.
Giveaway Announcement:
Winner announced above in the Giveaway Tools widget on February 12, 2013. Winners will be selected through Giveaway Tools and I will notify by email. Winner must respond within 4 days or the prize will be forfeited. Your email will not be shown and will be kept private.


text:
Pier 1 Reduces Skus To Up Sales
March 14, 2005-- Home Textiles Today,
Pier 1 Imports is focused on a less-is-more approach, reducing the number of skus it carries to accentuate a good, better, best segmentation that should improve sales, said Charles Turner, executive vice president and chief financial officer, during the Raymond James Institutional Investor Conference here last week.
"This year we are working hard to bring newness into the stores," he said. "We have cleared and edited our furniture lines from nine down to six, and four of those are new. We feel that by the end of April, we will be where we want to be."
Turner said that the company had gone from 4,500 skus down to 3,500 and currently sits between 2,800 and 3,000.
Turner said Pier 1 is taking a hard look at sales per square foot and looking to improve that number by keeping inventory fresh.
In fiscal 2005, he said the company opened 110 stores and closed 40 (including relocations). This year, Pier 1 plans to open 90 and close 20. "We are looking at real estate very carefully," said Turner. "We don't open stores just to reach a certain number."
Related Content By Author
Sponsored Content
Sponsored Links
Featured Video
Previewing Heimtextil 2017


text:
Philadelphia Eagles head coach Andy Reid is on the hot seat this season, but he may just be able to save his job thanks to some impressive young players such as Brandon Graham.
Reid has done a horrible job most of the year while leading the team to a 4-9 record so far. The one thing Reid has done well, however, is insert younger players into the lineup to see if they have anything significant to offer the franchise moving forward.
The move has paid off. Philadelphia has a cast of young players performing well for Reid, and it may just allow him to keep his job for at least one more season. With the following players looking great, it might not be a great idea to suddenly change head coaches.
Let's take a look at six players who could help Reid save his job.


text:
Manchin has lots to do on Obamacare
The disastrous $1 billion roll-out of the individual mandate in the Patient Protection and Affordable Care Act should be proof positive that the Obama administration is clueless.
What's more, there's plenty of cause for worry as universal health care coverage moves forward.
GOP Rep. Fred Upton of Michigan, chairman of the House Energy and Commerce Committee, posed scary questions during a hearing on Thursday.
"Will enrollment glitches become provider payment glitches? Will patients show up at their doctor's office or hospital only to be told that they aren't covered, or even in the system?"
Enrollment in the program has turned into an ugly mess. Want to sign up online? Good luck. The likely response: "Important: Your account couldn't be created at this time." You'll be told to call 1-855-889-4325. Good luck again. The likely response: static.
Thank you, Mister President.
Tea Party conservatives led by Sens. Ted Cruz and Mike Lee tried to warn everybody that Obamacare was not ready.
Last month, they backed a House GOP continuing budget resolution that would have funded government while imposing a one-year delay on implementation of the individual mandate. Democrats, establishment Republicans and media pundits said Cruz was nuts.
The government went into partial shutdown. The conservatives lost. The individual mandate took effect.
West Virginia Democratic Sens. Jay Rockefeller and Joe Manchin voted against a delay; Republican Rep. Shelley Moore Capito used a phony argument about debt default as she caved to the liberals.
Today, Tea Party conservatives don't look so crazy.
The Democrats' new game plan: Blame the website contractors for the sign-up problems, and yes, delay enforcement of the individual mandate by all means. And who better to push for delay than Joe Manchin, the senator who wanted a delay before he didn't want a delay?
(The morning of Sept. 26, if you'll recall, Manchin said there's "no way I could not vote for" a postponement of the individual mandate. "Don't put the mandate on the American public right now."
(A few hours later, however, Democratic leaders cleared his political throat for him. He repeated his position on the mandate but added, "That being said, I do not believe that this issue should be used to shut down the government, and I will not vote to shut down the government."
(Sen. Chuck Schumer, D-N.Y., later clarified Manchin's position for him. Schumer told the press that Manchin would be voting with Democrats and against a delay in the individual mandate.)
Manchin appeared on "The Factor" (Fox News) Wednesday night and with a straight face said that he's working on a bill to delay individual mandate penalties for a year.
He also told an incredibly gullible Bill O'Reilly, "I came here to fix things. Affordable health care was never meant to be, if you've got insurance now you're going to have to buy insurance that's more costly and not as good. That has to be fixed."
O'Reilly didn't ask Mister Fix-It why he bounced from supporting the mandate delay to opposing it to now supporting it, nor did O'Reilly challenge Mister Fix-It about higher premiums or other major flaws in
He should have. A lot of fixes are needed.
Regarding premium increases, Bob Laszewski, a health policy expert, says 16 million people are getting cancellation notices from their health insurers. If they want to re-enroll, they'll be able to, but with "pretty big rate increases."
Health care, itself, is going to be a huge issue, also.
Dr. Bradley Allen, a pediatric heart surgeon writing in the Wall Street Journal Tuesday, described Obamacare's "destructive effect" on the delivery of health care. Doctor shortages are going to get much worse, and some doctors already are refusing to accept new patients over the age of 50.
So Mister Fix-It, aka Sen. Manchin, has his work cut out for him, and the only question is: Will he have the backbone to do the right thing this time?


text:
Hawaii offers many great local events, and if you recently attended an event we'd love to see your photos and videos.
Upload your photos and videos to the Local Happenings category for them to appear in the slideshow above. Please include a brief description, along with the location of where the photo or video was taken. Your upload may be used on-air!
Start sharing today! Not a member? Join u local here it's quick and easy.


text:
More Images From New York's Sandy Cover
Stunning shots of the city with and without power.
The editor's letter in this week's New York Magazine tells the story of how the staff put the issue together after our downtown offices were flooded. Here is the story of how the striking photo on the cover of the issue came together.
As we considered the different opportunities for imagery on Wednesday, it quickly became clear that one option was a picture of the island of Manhattan taken from the air, showing the clear delineation of lights on and off in different parts of the city. We called Iwan Baan, one of our contributing photographers, to see if he happened to be in New York at the moment. (He is based out of Amsterdam, but travels the world, and often stops by New York.) Baan's photography focuses primarily on contemporary architecture and its relationship to the urban language of the city. He shoots from every possible perspective, including high up in the air from planes and helicopters. "That view of Manhattan, I had it in mind because I'd shot it a number of times before," he said on Monday from Haiti, where he's already on another international assignment.
Fortunately, Baan was in town last week and had prepared for the storm. "Before the hurricane hit, I had already decided that it could be very difficult to get out of the city," Baan explained. "I was in Tokyo last year during the tsunami and the earthquake and experienced the moment of panic breaks out in a big city. So as a precaution I had already booked a rental car for the day after, just in case."
But when he got to Hertz in Manhattan, they had run out of vehicles. "I made kind of a scene," Baan admitted, "and in the end they said, 'We have a car for you but it's at JFK Airport and instead of $300, it's now $2,000 for the week.' It took me about four hours to get to JFK in a cab and when I finally got there, it was late in the afternoon. It was literally the last car in town."
Then he had to track down a helicopter. "I started to call around the pilots that I usually use, but they were already out of gas or power or on a rescue mission, so none of them could help. I finally found one about an hour and a half drive away in Long Island, but they said they only accepted cash because the hangar didn't have power. Luckily, I had also gone to the ATM before the storm and I had enough cash with me, so it all lined up perfectly."
"I was already in Brooklyn, so I didn't have to get out of the city anymore," said Baan. "I drove straight there." Total flight time was two and a half hours: one hour to get to Manhattan, half an hour shooting time over the city, and one hour back to eastern Long Island. It was a clear night with wonderful visibility and just enough cloud presence to make for a beautiful sky.
"It's quite difficult to shoot from a moving helicopter even during the day because of the vibrations," he said. "It was super dark so I had to shoot with a long shutter time, and I could only do it because I had just gotten the newest Canon" —a 1D X with a 24-70mm lens — "which is more sensitive. I shot between 2,000 and 2,500 shots — 80 percent of the shots are a blur, 10 percent are maybe useable, and 1 percent were really sharp.
"It was very uncertain, but I knew it would be an amazing shot of New York at that moment. All these details of the day just lined up. If one of the things didn't line up, the shot wouldn't have been possible."
Here, we present ten images from the shoot, including the cover, which appears first. We've published them on the Cut to take advantage of the full-screen zoom functionality available on that site.BEGIN SLIDESHOW


text:
Thanksgiving JournalPosted at 10:44 PM | Comments (3)
My Mom started a tradition the year my sister died that we do on Thanksgiving. She took a journal in which my sister only wrote on the first page and she put it out on the Thanksgiving table during the feast and festivities. It became our family Thanksgiving journal. If any of us feels led, then we write in the journal. It is pretty neat going back and reading the things over the years. The neices and nephews (the young ones) occassionally write in it as well... their comments are often cute. It will be fun to watch them mature from year to year in their entries.
One of my personal and favorite entries was giving thanks for having Johnny, 11 years into our marriage and after having trouble getting pregnant. He would have only been a few weeks old the year I wrote that. So many great and small things to be thankful for...
We love the tradition, because like many folks that have lost loved ones or have broken relationships or personal struggles, the holidays can sometimes be difficult or have difficult moments. But having the journal reminds us that even in the midst of pain, there is so much thanks to be given. And that journal will be a great treasure in our family for generations to come. Having lost Amy, we realize that every moment with our family and friends is a gift. And I am truly blessed beyond measure.
Social Media


text:
Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
your express consent. For more information, please refer to our Privacy Policy.
Al‐Jarallah, Khaled MD, FRCPC1,*; Shehab, Diaa MD, FRCPC1; Al‐Attiyah, Rajaa MD, PhD2; Al‐Azmi, Waleed MD, FRCPC1; Al‐Fadli, Ahmad MD, FRCPC3; Zafar Haider, Mohammed MD, PhD4; Panaccione, Remo MD, FRCPC5; Ghosh, Subrata MD, FRCPC5
Background:: Antibodies that react with citrullinated proteins (anti‐mutated citrullinated vimentin [anti‐MCV] and second‐generation anti‐cyclic citrullinated peptide antibodies [anti‐CCP2]) are markers for rheumatoid arthritis. Recent studies have demonstrated that these antibodies are present in other arthropathies including the spondyloarthritis, psoriatic arthritis, and juvenile idiopathic arthritis. Arthritis associated with inflammatory bowel disease (IBD) takes various forms, with some shared similarities with classic spondylarthropathies. Our objective was to investigate the role of anti‐MCV and anti‐CCP2 as potential biomarkers in IBD and related arthritis.
Methods:: In all, 125 IBD patients (71 males, 54 females) were compared to 81 age‐ and sex‐matched healthy controls. Anti‐MCV and Anti‐CCP2 IgG were measured using an enzyme linked immunosorbent assay.
Results:: In the 125 IBD patients (mean age 32.6 ± 12.3 years), 44 (35.2%) had ulcerative colitis and 81 (64.8%) had Crohn's disease. Forty‐four (35.2%) IBD patients developed arthritic manifestations. Antibody positivity was observed in 24/125 (19.2%) IBD patients and in 18/81 (22.2%) healthy subjects. The proportion of anti‐MCV positivity among IBD patients and healthy individuals were similar: 16.8% vs. 16.0%, P = 0.887. Anti‐CCP2 positivity among IBD patients and healthy individuals was also comparable: 6.4% vs. 6.2%, P = 0.948. Similarly, the presence of anti‐MCV and anti‐CCP2 antibodies was not different among IBD patients with and without arthritis. The mean titers of antibodies were low: anti‐MCV (29.6 ± 7.5 U/mL) and anti‐CCP2 (27.6 ± 4.0 U/mL) in IBD patients with arthritis.
Conclusions:: Autoantibodies to citrullinated proteins were low in IBD‐related arthritis. These findings suggest that these antibodies are not useful biomarkers in IBD to predict who may develop IBD‐related arthropathy. (Inflamm Bowel Dis 2012)
© Crohn's & Colitis Foundation of America, Inc.
Colleague's E-mail is Invalid
Your Name: (optional)
Your Email:
Colleague's Email:
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at Inflammatory Bowel Diseases.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
Folder Name:
The item(s) has been successfully added to "".
You currently do not have access to this article.
You may need to:
Note: If your society membership provides for full-access to this article, you may need to login on your society's web site first.
Login with your LWW Journals username and password.
Username or Email:
Forgot Password?
Need to Activate a New Subscription?Recently purchased a subscription? Login or Register a new account
and enter your subscription ID, or Subscribe Now!
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection
Article Level Metrics
arthritis, anti-cyclic citrullinated peptide antibodies, anti-mutated citrullinated vimentin, inflammatory bowel disease, spondylarthropathies
Search for Similar Articles
You may search for similar articles that contain these same keywords or you may
modify the keyword list to augment your search.


text:
There's no more beautiful place for your wedding than Dominica, the Nature Island.
It's very easy to have a wedding in Dominica. Couples can get married within 24 hours.
Read through the requirements below and then use our Where to Stay
page to select the hotel that best suits your style and your budget.
Fort Shirley,
Cabrits National Park
A Beautiful Venue for a Wedding!
More about Fort Shirley...
Need a Photographer for
Your Wedding?
Images Dominica.com
Hotels offering Honeymoon Packages:
Guidelines for Obtaining a Special Marriage Licence in Dominica
The following guidelines are from the Government of Dominica's website here:
Please note:
more information contact the Ministry of Community Development on.
Ministry of Social Services, Community Development and Gender Affairs
1st Floor, Government Headquarters
Kennedy Avenue
Tel: (767) 448 2401
E-mail: firstname.lastname@example.com
Need Help finding a Hotel for your Wedding, Reception or Honeymoon?
Many hotels here in Dominica will be happy to assist you with organising your wedding, reception and accommodation for the bride and groom, wedding party, and family and friends.
For your perfect honeymoon, browse teh featured hotels at left, or see our Accommodation Wizard page and tick the "Honeymoon Package" box under Step 2.


text:
Does anybody know if you can SoB bosses, or do they still grab you even if you successfully hit them??
Awww they brought the golden scarabs back too? Wow!
batman is a pretty sweet game for the wiiu gamepad
lol at 9:56 he said God created the World in "Seven" days. its 6 days not 7 lol
anyway nice ^^
Pad with screen and Pro controller
Can you play on the gamepad?
I really hate Regent. There doesn't seem to be a guaranteed safe time to attack him. He just dodges everything, even after completely missing a huge attack.
Moar please
Too be a hundred percent honest, the only definitive reason I'd like to purchase a Wii U right now is for this version of NG3. I was just playing the original a couple hours ago, and comparing this with it, there's no contest. They basically add all the stuff that was missing from the original, and added a little NG2 flavour.
use the dragon sword men (:
damn really? took me only 3 or 4 tries. But if u can leave alot of the deaths in, that would be cool. I like to compare how other people play. To me, playing the same game.
The end took me more then 30 minutes…
awesome man. And please dont edit out ur deaths. I like to see how many times it takes to get past certain parts.
I wanna know if this one is like Sigma 2, that has some missions multiplayer with Ayane
We'll see. 🙂
I'll beat you to it next time
part 4 plz
Ninja Gaiden 3 Razor's Edge: Day 1 Ryu Hayabusa – Walkthrough Part 3 [HD]
Written by admin
Freitag, 03 Mai 2013 01:35
18 Comments
Freitag, 03 Mai 2013 01:35
18 Comments
18 Comments
Leave a Reply
You must be logged in to post a comment.


text:
Marc Chagall L'atelier de Paris (gouache, 1969)
Chagall's work embodies a deep passion for life. He took inspiration from his Belarusian background, employing symbolic motifs and folk art – often with Biblical themes. His work encompassed stained glass windows and tapestries, in addition to his paintings and etchings.
The Rothschild name has long been associated with appreciation of culture and patronage of the arts, which continues to this day.
About the images
The Rothschild office in Zurich is home to a superb art collection. There are over 200 works of art on display and in the archives, including pieces by Pop Artists such as Lichtenstein and Warhol, and a large Christo collection. Some of the images featured on this website are from this collection. Each of them reflects our theme of 'shaping wealth for generations'.


text:
Jennifer Lopez Dismisses Engagement Rumors: 'Don't Be Fooled By The Rocks That I Got'
Jennifer Lopez directly dismissed rumors that she's engaged to boy-toy Casper Smart with a post on her official website that simply referenced her 2002 hit, "Jenny From The Block."
"Rumors!!! Don't be fooled by the rocks that I got. No engagement!" she exclaimed on her site Friday after being spotted earlier this month with a ring on her wedding finger.
Lopez, 42, and Smart, 25, began dating last November, mere months after she and huband Marc Anthony filed for divorce.
J. Lo finally opened up about her new relationship in the April issue of Vogue magazine; saying, "He's adorable. But you already see that... He is. He really is. He's a good egg. I don't want to talk about it too much. It's my private thing."
Another false rumor started in March, when fashion designer Roberto Cavalli tweeted that Lopez asked him to "create a special dress. For her next weding! (sic)"
The (former?) American Idol judge and her backup dancer have been working together a lot lately - the couple got super-steamy in her "Dance Again" video in April; and Smart directed his lover in tour-mates Wisin y Yandel's latest video, "Follow the Leader."
As far as the couple's 18-year age difference goes - Lopez says, "I don't feel older and I don't feel like I look it, either, so I'm just acting the same way I have always acted."


text:
Transgenic zebrafish as a Tool for Looking at the Effects of Environmental Toxicants on DevelopmentWe use gene trapping to create transgenic zebrafish expressing fluorescent proteins in different cells or tissues during developments. The light emitted by the fluorescent protein allows one to follow its expression, and the cells expressing the fluorescent protein during development using a fluorescent microscope. We can determine the effects of environmental toxicants on particular cell types expressing the fluorescent proteins via fluorescent microscopy. Also, we use PCR based techniques to locate where in the zebrafish genome the transgene is inserted.
This project is located at the School of Freshwater Science: 600 E. Greenfield Ave. Milwaukee, WI 53204
***Campus Shuttle Service to The School of Freshwater Science is now available!***
Tasks and responsibilities:Zebrafish husbandry: Including feeding, spawning, collecting and observing embryos and larval fish. Microscopy: Using stereomicroscopes, inverted and upright microscopes and recording observations using high end CCD cameras. Molecular Biology: RNA/DNA isolation, polymerase chain reaction Bioinformatics.


text:
These types of bulbs, if unbroken, should be collected by Facilities Management.
These types of bulbs may be disposed of in general trash, to be collected by Housekeeping.
Fluorescent bulbs do contain a small amount of mercury sealed within the glass tubing which can be released after a breakage. For this reason, EHS should be contacted to clean up and collect any debris from a broken fluorescent bulb. Simply fill out the Chemical Pick-Up Request form. This form will ask who you are and what room and building the broken bulbs are in. If you have any special instructions like where the bulbs are located within the room, or if you have special instructions on when the pick-up should occur, you can enter this information in the comments section. The form will be submitted electronically to several members of EHS and someone will come and pick up the broken bulbs as soon as possible.
Broken incandescent bulbs may be placed in the broken glass container for eventual collection by Housekeeping. If you are uncertain whether your broken bulb is incandescent or fluorescent, please err on the side of caution and contact the EHS office for advice.